Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Mezigdomide overcomes CRBN mutations emerging post IMiD therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

EWEdmond R. WatsonCBChad C. BjorklundOPOlivia Pierce

Discussion

Loading...

Member takes

Overview

Pre-clinical investigation shows mezigdomide targets CRBN mutations, enhancing drug efficacy in multiple myeloma patients.

Key Points

  • To explore how mezigdomide overcomes CRBN mutations in multiple myeloma after IMiD therapy.
  • Profiled CD138+ sorted samples from multiple myeloma patients using whole genome sequencing.
  • Identified unique CRBN mutations and their effects through 3D modeling and metadynamics simulations.
  • Conducted functional assays to evaluate drug interactions with the A365D CRBN mutation.
  • Identified 34 unique CRBN mutations with various impacts on protein stability and drug efficacy.
  • Mezigdomide showed enhanced degradation of IKZF-family proteins despite the presence of the A365D mutation.
  • Demonstrated that the A365D mutation alters drug binding, affecting treatment outcomes in multiple myeloma.

Cite This Study

Watson et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d00ahttps://doi.org/10.1182/blood-2025-436
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 1792: Comprehensive identification of factors involved in the resistance mechanism of a novel cereblon modulator in multiple myeloma cells2026
  2. 2Pharmacodynamic activity and clinical benefits of mezigdomide in high-risk biomarker subgroups from the CC-92480-MM-001 study2025
  3. 3Targeting Ikaros and Aiolos: Next‐Generation Cereblon <scp>E3</scp> Ligase Modulators in <scp>MM</scp>2026
  4. 4Targeting degradation of IKZF1 and IKZF3 through modulation of the E3 ligase substrates in the context of cellular therapies for multiple myeloma2025 · 7 citations
  5. 5EZH2 inhibition overcomes immunomodulatory drug resistance in multiple myeloma via a cereblon-dependent pathway2026 · 1 citations